A small Cambridge, Massachusetts-based company is hoping its bet on CNS drugs using a well established pharmaceutical approach — allosteric modulators — will cement its place as a biotech powerhouse in the years to come. Cadent Therapeutics — currently a 9-person team — has already found a partner in Novartis $NVS.
A lot has been written about the biotech talent war in the Boston area including the availability of talent as the major limitation to venture creation and the increasingly lavish perks designed to attract and retain experienced staff. As the leader of an organization attempting to grow within this ecosystem, I am acutely aware of the challenges.
This blog was written by Aoife Brennan, CEO of Synlogic, as part of the From The Trenches features of LifeSciVC.
You can add Kymera Therapeutics to the list of biotechs attracting attention from an international set of investors.
2018 has so far been another gangbuster year for biotech IPOs: the first three quarters of the year have delivered nearly 50 new biotech offerings, reinforcing the strong new issuance performance of the past 6 years.
After last year’s inaugural success, we’re excited for 2019’s Science2Startup conference in April 2019, an invitation-only university-focused biotech entrepreneurship event aimed at building connectivity across the academic, tech transfer, and venture communities.